Prediction of lung cancer patients’ response to combined chemo-radiotherapy using a personalized hybrid model

The paper presents a novel approach to the prediction of the combined therapy outcome for non-small lung cancer patients. A hybrid model is proposed, consisting of two parts. The first one is a mathematical model of tumor response to therapy, whose parameters are expressed as linear function of data from massspectrometry of patient blood plasma samples. These linear functions constitute thesecond component of the hybrid model. A comparison of clinical and simulation-based survival curves is used to evaluate the quality of the model.